Provider Briefing: Aimovig Access in 2026

If your migraine patients are reporting difficulty filling their Aimovig (Erenumab-aooe) prescriptions, you're not alone. While Aimovig is not in a formal shortage, the combination of specialty pharmacy logistics, insurance gatekeeping, and single-manufacturer supply creates persistent access friction for patients who depend on this medication.

This article provides a concise, evidence-based overview of the current Aimovig availability landscape — written for neurologists, headache specialists, primary care providers, and clinical staff who prescribe CGRP inhibitors.

Supply Status Timeline

• May 2018: FDA approval of Aimovig — the first CGRP receptor antagonist for migraine prevention. Manufactured by Amgen in partnership with Novartis.
• 2018–2022: Broad commercial launch. Insurance coverage expanded, though prior authorization and step therapy remained standard across most payers.
• Early 2023: Patient-reported supply disruptions at certain pharmacies. No formal FDA shortage listing. Issues were primarily distribution-related.
• 2024–2025: Continued intermittent patient reports of difficulty filling prescriptions, particularly around insurance plan year changes (Q1) and specialty pharmacy transitions.
• Early 2026: Aimovig is not listed on the FDA Drug Shortage Database. No manufacturing disruptions reported by Amgen. Access issues persist but are attributable to distribution and payer barriers rather than supply constraints.

Prescribing Implications

Formulary and Coverage Landscape

Aimovig remains on most commercial and Medicare Part D formularies, though coverage varies significantly:

• Prior authorization: Required by the majority of commercial plans. Typical criteria include documented diagnosis of episodic or chronic migraine, failure of 2-3 preventive medications (step therapy), and ongoing migraine frequency documentation.
• Step therapy: Most payers require documented trial and failure of medications such as Topiramate, Propranolol, Amitriptyline, or Venlafaxine before approving CGRP inhibitors.
• Preferred CGRP agent: Some plans preferentially cover one CGRP inhibitor over others. If Aimovig is non-preferred on your patient's formulary, another CGRP agent (Ajovy, Emgality, Vyepti, or Qulipta) may have lower cost-sharing or fewer barriers.
• Specialty tier placement: Aimovig is typically on a specialty tier (Tier 4 or 5), meaning higher copays even with coverage.

Clinical Considerations When Switching

If a patient cannot access Aimovig, switching to another CGRP inhibitor is clinically reasonable:

• Mechanism differences: Aimovig blocks the CGRP receptor; Ajovy, Emgality, and Vyepti target the CGRP ligand. Some patients respond to one mechanism but not the other — a switch may be therapeutic, not just logistical.
• Transition timing: Given Aimovig's approximately 28-day half-life, initiating an alternative around the time the next Aimovig dose would be due is generally appropriate.
• Oral option: Qulipta (Atogepant) offers daily oral dosing for patients who prefer to avoid injections or who face injection-specific insurance barriers.
• IV option: Vyepti (Eptinezumab) may be preferable for patients with adherence concerns, as it's administered quarterly in-office.

Current Availability Picture

Aimovig is generally available through the specialty pharmacy channel. Key distribution facts:

• Sole manufacturer: Amgen Inc.
• No biosimilar: No biosimilar version of Erenumab is approved or imminently expected.
• Primary distribution: Specialty pharmacies (Accredo, CVS Specialty, OptumRx Specialty, AllianceRx Walgreens, Biologics by McKesson, and others).
• Retail pharmacy availability: Limited. Most retail pharmacies do not routinely stock Aimovig.
• Home delivery: Available through most specialty pharmacy channels. Cold-chain shipping is standard.

When patients report they "can't find" Aimovig, the root cause is more often insurance authorization failure, pharmacy channel mismatch (trying to fill at a retail pharmacy), or expired prior authorization than actual product unavailability.

Cost and Access Overview

• Wholesale acquisition cost: Approximately $750–$1,100/month depending on dose.
• Aimovig Co-Pay Card: Commercially insured patients may pay as little as $5/month (up to program maximums). Not valid for government insurance.
• GoodRx cash-pay program: Approximately $299/month for uninsured or cash-pay patients.
• Amgen Safety Net Foundation: Free medication for eligible uninsured or underinsured patients meeting income criteria. Applications through Amgen SupportPlus.
• Amgen SupportPlus: Comprehensive patient support including insurance navigation, copay assistance, and pharmacy coordination. Phone: 1-888-4AIMOVIG (1-888-424-6684).

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder helps patients and providers check real-time pharmacy availability for medications including Aimovig. Rather than having your staff call multiple pharmacies, direct patients to Medfinder or check availability from your end.

Prior Authorization Support

Amgen provides prior authorization resources including pre-filled appeal templates and payer-specific criteria checklists. These can significantly reduce staff burden when navigating coverage denials.

Patient Education Materials

Consider sharing these resources with patients who are having difficulty:

• How to find Aimovig in stock near you
• How to save money on Aimovig
• Patient-facing shortage update

Looking Ahead

Several trends may affect Aimovig access in the coming months:

• Biosimilar pipeline: While no Erenumab biosimilar is approved, the CGRP class is maturing. Increasing competition among branded CGRP agents may improve payer coverage and pricing flexibility.
• Oral CGRP expansion: As oral gepants like Qulipta gain market share, some payers are adjusting their step therapy algorithms, potentially affecting injectable CGRP coverage patterns.
• Payer consolidation: Ongoing changes in pharmacy benefit management may affect which specialty pharmacies patients are required to use, creating new logistical hurdles even when supply is adequate.

Final Thoughts

Aimovig access in 2026 is not a supply problem — it's a systems problem. The medication is being manufactured, but the path from manufacturer to patient involves enough intermediaries, authorizations, and restrictions that gaps are common.

As prescribers, the most impactful things we can do are: check formulary preference before prescribing, proactively submit prior authorizations with thorough documentation, direct patients to specialty pharmacy and support resources, and have a backup plan (alternative CGRP agent) ready if access fails.

For a comprehensive provider toolkit, visit Medfinder for Providers. For practical guidance on helping patients navigate pharmacy availability, see our companion article: How to help your patients find Aimovig in stock.